PDCD1 and neoplasm: Notably, PDO retained both the parental genetic tumor abnormalities and the native intra-tumoral T cell receptor repertoire of CD3+ TIL and allowed to evaluate the enhancement of their tumor-specific cytotoxic function upon IC blockade with the anti-PD-1 antibody nivolumab [101].